Related Experiment Video
Updated: Mar 6, 2026
05:39
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
Published on: May 16, 2025
781
Evidence- and consensus-based guideline on lichen sclerosus.
Gudula Kirtschig1, Linn Woelber2, Andreas Günthert3
1Medbase Health Centre Frauenfeld, Frauenfeld, Switzerland.
Summary
The S3 guideline for lichen sclerosus (LS) offers evidence-based recommendations for diagnosis and treatment in German-speaking countries. Topical corticosteroids remain the standard therapy for genital LS across all ages.
Area of Science:
- Dermatology
- Guideline Development
- Evidence-Based Medicine
Background:
- Lichen sclerosus (LS) is a chronic inflammatory skin condition requiring standardized management.
- Previous European guidelines exist, necessitating adaptation for German-speaking healthcare contexts.
Purpose of the Study:
- To develop a German S3 guideline for lichen sclerosus (LS).
- To provide consensus- and evidence-based recommendations for diagnosis, management, and treatment tailored to German-speaking countries.
Main Methods:
- Consensus- and evidence-based approach.
- Adaptation of the European EuroGuiDerm Guideline.
- Interdisciplinary expert group including patient representatives.
Main Results:
- Comprehensive recommendations for diagnosis, patient management, follow-up, and education.
- Standard therapy for genital LS: ultrapotent/potent topical glucocorticosteroids with emollients.
- Circumcision indicated for LS-associated phimosis unresponsive to therapy in males.
- Phototherapy recommended for extragenital LS; topical calcineurin inhibitors as second-line.
Conclusions:
- The guideline provides a standardized framework for managing lichen sclerosus (LS) in German-speaking regions.
- Topical corticosteroids are confirmed as first-line treatment for genital LS.
- Specific recommendations address extragenital LS and treatment-resistant cases.
